![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients
Receiving Pangenotypic Direct-acting Antivirals for the Treatment of Hepatitis C
|
|
|
AASLD 2021 Nov 12-16
Juan Turnes1, Antonio García-Herola2, Ramón Morillo3, Marinela Méndez4, Magdalena Rueda4, Cándido Hernández5, Antoni Sicras-Mainar6
1Gastroenterology and Hepatology Department, CHU. Pontevedra, Spain; 2Digestive Medicine Department. Hospital Marina Baixa de Villajoyosa (Alicante), Spain; 3Hospital Pharmacy, Hospital de Valme, AGS Sur de Sevilla, Spain; 4Medical Affairs, Gilead Sciences S.L., Madrid, Spain; 5Global Medical Affairs, Gilead Sciences Europe Ltd, U.K; 6Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain
![1113211](../images/111321/111321-7/1113211.gif)
![1113212](../images/111321/111321-7/1113212.gif)
![1113213](../images/111321/111321-7/1113213.gif)
![1113214](../images/111321/111321-7/1113214.gif)
![1113215](../images/111321/111321-7/1113215.gif)
![1113216](../images/111321/111321-7/1113216.gif)
![1113217](../images/111321/111321-7/1113217.gif)
![1113218](../images/111321/111321-7/1113218.gif)
![1113219](../images/111321/111321-7/1113219.gif)
![11132110](../images/111321/111321-7/11132110.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|